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METASTATIC KIDNEY CANCER TREATED WITH MULTIPLE DRUG
THERAPY AT THE ROTTERDAM RADIOTHERAPY INSTITUTE
Sir,-Price and Goldie (1971) reported
promising preliminary results of multiple
drug therapy in the treatment of metastatic
solid cancer. Based on these data it was
decided to assess the possibilities of a slightly
modified form of treatment in patients with
metastatic kidney cancer.
Between 1971 and 1973 18 patients were
submitted to multiple drug chemotherapy
(Table). All patients had proven adeno-
carcinoma of the kidney. The histological
diagnosis wasmade either onthenephrectomy
TABLE.-Rotterdam Radiotherapy Institute
Multiple Drug Therapy
At 0 h
Cyclophosphamide 700 mg/M2, max. 1 g i.v.
5-fluorouracil 500 mg/M2, max. 1 g i.v.
Vincristine 1 mg/M2, max. 2 mg i.v.
Methotrexate 25 mg/M2, in a 6 hours infu-
infusion sion, 4 times. Total
max. 200 mg.
At 24 h
120 mg folinic acid i.v.
At 30 h
15 mg folinic acid i.m., 5 times, at 6 h intervals
Repeated every 4 weeks.
specimen or on a biopsy taken from a
metastasis. All patients had multiple skele-
tal-and/or lymph node-and/or soft tissue-
and/or visceral metastases. All patients
had measurable signs of progressive growth
of their malignancy.
Pulmonary metastases were not con-
sidered to be reliable for assessing progress
of metastases as in a previous study it
became evident that these metastases have
a tendency towards unpredictable spon-
taneous fluctuation and regression (Werf-
Messing and Gilse, 1971).
Painful or "dangerous" lesions, for
instance metastases with risk of fracture,
cord compression, inferior vena cava obstruc-
tion, etc, were treated by radiotherapy.
Eighteenpatients (4females and 14 males)
selected according to the above mentioned
criteria, received multiple drug therapy.
The majority of patients had previously
been treated unsuccessfully with megestrol
acetate, 60 mg daily. The average age of
the patients was 61 years.
Because of serious complications, pro-
gressive metastases or death in spite of
chemotherapy, only one course was given
in 2 cases. For the same reasons treatment
was not repeated after two courses in 5
cases; 11 patients received three or more
courses ofmultiple drug therapy.
In no case could objective response to
chemotherapy be detected. Slight subjective
improvement was observed in one patient.
In another case it was doubtful whether
subjective improvement was real or just the
improvement after recovery from side-effects
of chemotherapy.
As a rule the complications of this
treatment were not severe: severe nausea
(6 cases), severe thrombopenia (1 case),
loss of hair (2 cases, of which one in com-
bination with severe nausea), cardiac failure
(1 case), ulceration of buccal mucosa (3
cases), sepsis (1 case), candida infection
(1 case).
Though the report of Price and Goldie
was encouraging, kidney cancer patients
at the Rotterdam Radiotherapy Institute
had no demonstrable objective benefit by
multiple drug therapy. The complication
rate would have been acceptable had the
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treatment yielded any objective response or
more subjective improvement.
In view of the negative results this
multiple drug therapy schedule has been
abandoned.
B. VAN DER WERF-MESSING
J. MUTLDER
Rotterdam Radiotherapy Institute
Groene Hilledijk 297
Rotterdam-3024
The Netherlands
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